ALDX Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, wh…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease Aldeyra Therapeutics (NASDAQ:ALDX) said it plans to submit a formal dispute resolution request, or FDRR, to the FDA’s Office of New Drugs seeking review of the agency’s latest complete response letter for reproxalap, its investigational treatment for the signs and symptoms of dry eye disease. The c | ||
 Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter Aldeyra Therapeutics intends to formally challenge the FDA’s March 2026 rejection of reproxalap for dry eye disease, with a Formal Dispute Resolution Request and meeting with the agency’s Office of New Drugs expected in the fourth quarter of 2026. Key Investor TakeawaysAldeyra Therapeutics (NASDAQ:ALDX) plans to submit a Formal Dispute Resolution Request seeking to appeal the FDA’s March 16, 2026 Complete Response Letter for reproxalap. | ||
 Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 ACAD gains a potential patent extension for Daybue to 2041, while strong sales growth and EU approval expand trofinetide's reach. | ||
 ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal Acadia stock falls 13% after its Alzheimer's psychosis study narrowly misses its primary goal, though 60 mg results support continued phase III development. | ||
 IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down Immunovant's IMVT-1402 misses its primary CLE goal, prompting the company to halt the program despite positive trends and a favorable safety profile. | ||
 ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data Oruka's ORKA-001 delivers deeper psoriasis clearance at week 28, but safety disclosures may have weighed on shares despite positive efficacy data. | ||
Vertex Posts Positive Phase II Data on Kidney Disease Drug VRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027. | ||
XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback Xenon files an FDA application for azetukalner in epilepsy as its depression studies face a temporary enrollment pause. | ||
 RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy Ultragenyx jumps 13% after FDA approval of Fayuvi, the first approved treatment for Sanfilippo syndrome Type A, backed by durable clinical data. | ||
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth. | ||
 Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy. | ||
 Definium Reports Second Phase III Success in Anxiety Disorder Program DFTX scores a second phase III GAD win as DT120 ODT delivers significant anxiety improvements, paving the way for FDA talks and a planned 2027 regulatory filing. | ||
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study SYRE's SPY003 posts positive phase II UC data, strengthening Spyre's multi-mechanism IBD strategy. | ||
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why VSTM shares surge 121% as Avmapki Fakzynja Co-Pack gains commercial traction and VS-7375 advances across key cancer studies. | ||
CAPR Stock Skyrockets 144% in a Month: What Is Driving the Rally? Capricor shares jump in a month as positive phase III data and renewed FDA engagement revive hopes for deramiocel approval in DMD. | ||
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally? KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth. | ||
FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis FDA accepts United Therapeutics' Tyvaso sNDA for an IPF label expansion, backed by TETON data showing improved lung function and reduced clinical worsening. | ||
 RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals Ultragenyx plunges 46% after its phase III Angelman syndrome study fails to achieve key efficacy goals, putting apazunersen's future in question. | ||
Here's Why You Should Add RNTX Stock to Your Portfolio Now Rein Therapeutics advances LTI-03 in IPF. RENEW enrollment tops 25%, with interim data expected in the fourth quarter of 2026. | ||
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know Kura's rising Komzifti sales, promising AML data and pipeline catalysts boost investor confidence and fuel KURA's gains. | ||
Here's Why You Should Add ARQT Stock to Your Portfolio Now Arcutis raises its 2026 revenue guidance as Zoryve gains momentum, expands into younger patients and advances potential new indications. | ||
Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection GILD wins FDA approval for Bixlenvo, a once-daily HIV regimen offering a smaller single-tablet option for patients on complex therapies. | ||